Drug intelligence / Profile preview

depigoid + grasses pollen + olea europaea pollen

Development stage
Phase 3
Lead developer
Leti Pharma
Modality
Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

Depigoid + grasses pollen + olea europaea pollen is a combination immunotherapy product that contains depigmented polymerized extracts of grass pollen and olive tree (olea europaea) pollen. It is used for allergen-specific immunotherapy (subcutaneous immunotherapy, SCIT) in the treatment of allergic rhinitis, rhinoconjunctivitis, and/or allergic asthma caused by sensitization to grass and olive pollen. The depigmentation and polymerization processes reduce IgE binding while maintaining T-cell reactivity, improving tolerability and reducing the risk of systemic allergic reactions compared to native extracts[3][7]. The mechanism of action is immunomodulation—repeated exposure to small quantities of allergens re-trains the immune system to reduce allergic responses over time[2][3][7]. Developed primarily for moderate-to-severe pollen-induced conditions, especially in regions with high grass and olive tree pollen exposure.

Brand names
Depigoid DUO
Other names
Depigoid Gräser + Olea europaea pollenDepigoid Grass Mix/olea europaeadepigmented polymerized allergen extracts mixture

Beyond the preview

Go deeper on depigoid + grasses pollen + olea europaea pollen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on depigoid + grasses pollen + olea europaea pollen.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call